SCHEMBL7046945

SCHEMBL7046945

COc1cc(CC(=O)Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.57
KDM4E B2RXH2 1/20 0.54
HTR2A P28223 1/20 0.52
HTR2C P28335 1/20 0.52
HTR2B P41595 1/20 0.52
KMT2A Q03164 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 1/20 0.50
CYP3A4 P08684 1/20 0.50
MAPT P10636 1/20 0.50
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
GAA P10253 1/20 0.50
ALOX12 P18054 1/20 0.49
MAPK10 P53779 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
MAPK1 P28482 1/20 0.49
CYP2C19 P33261 1/20 0.49
POLB P06746 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10411180 0.90 PTGS2 (0.57) PTGS2KDM4EHTR2AHTR2CHTR2B
SCHEMBL8772755 0.90 PTGS2 (0.52) PTGS2KDM4EHTR2AHTR2CHTR2B
SCHEMBL8931216 0.87 PTGS2 (0.48) PTGS2KDM4EHTR2AHTR2CHTR2B
SCHEMBL4965033 0.86 PTGS2 (0.55) PTGS2KDM4EHTR2AHTR2CHTR2B
SCHEMBL2307800 0.86 PTGS2 (0.55) PTGS2KDM4EHTR2AHTR2CHTR2B
SCHEMBL499116 0.86 GAA (0.61) PTGS2KDM4EHTR2AHTR2CHTR2B
SCHEMBL7774569 0.86 PTGS2 (0.47) PTGS2KDM4EHTR2AHTR2CHTR2B
SCHEMBL8160430 0.85 TUBB1 (0.68) ALDH1A1GAA
SCHEMBL4240508 0.84 PTGS2 (0.53) PTGS2KDM4EHTR2AHTR2CHTR2B
SCHEMBL2272890 0.84 PTGS2 (0.53) PTGS2KDM4EHTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104230935-A Anti-tumor effect and application of compound containing alicyclic structure LIAONING LIFENG TECHNOLOGY DEV CO LTD 2014-12-24 CN disclosed
CN-102241678-B Anti-tumor effect and application of alicyclic structure-containing compound LIAONING LIFENG SCIENTIFIC & TECHNOLOGY DEVELOPMENT Co.,Ltd. (CN) 2014-10-29 CN disclosed
CN-101367749-B A set of mesidino mesitoyl derivant, preparation and application thereof INST MEDICINAL BIOTECHNOLOGY 2013-04-24 CN disclosed
CN-102241678-A Anti-tumor effect and application of alicyclic structure-containing compound LIAONING LIFENG TECHNOLOGY DEV CO LTD 2011-11-16 CN disclosed
CN-101367749-A A set of mesidino mesitoyl derivant, preparation and application thereof MEDICINE AND BIOENGINEERING IN (CN) 2009-02-18 CN disclosed
US-20030139477-A1 Polyhydroxylated benzene-containing compounds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-07-24 US disclosed
US-4845129-A ANTICOAGULANT SANDOZ PHARM. CORP. (US) 1989-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139477-A1 Polyhydroxylated benzene-containing compounds LIPE, PNLIP, SHBG PTGS2 1440/4885KDM4E 1521/4885HTR2A 1266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.